A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA).

ABSTRACT:

Background

The optimal treatment of recurrent ovarian clear cell carcinoma remains unknown. There is increasing rationale to support the role of immune checkpoint inhibitors targeting the programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) axis in ovarian clear cell carcinoma.

Primary objective

To evaluate the efficacy of durvalumab (MEDI-4736) compared with standard chemotherapy in patients with recurrent ovarian clear cell carcinoma.

Study hypothesis

Patients with recurrent ovarian clear cell carcinoma treated with durvalumab will have improved progression-free survival compared with those treated with chemotherapy of physician's choice.

Trial design

The MOCCA study is a multicenter, open-label, randomized phase II trial in patient

SUBMITTER: Ngoi NY 

PROVIDER: S-EPMC7418587 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature